Article
The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients.
The pharmacogenomics journal - 1 Jun 2010
Schenk P W, van Vliet M, Mathot R A A, van Gelder T, Vulto A G, van Fessem M A C, Verploegh-Van Rij S, Lindemans J, Bruijn J A, van Schaik R H N
Abstract excerpt
CYP2C19 converts the tricyclic antidepressant imipramine to its active metabolite desipramine, which is subsequently inactivated by CYP2D6. The novel CYP2C19*17 allele causes ultrarapid metabolism of CYP2C19 substrates. We genotyped 178 depressed patients on imipramine for CYP2C19*17, and measured steady-state imipramine and desipramine plasma concentrations. Mean dose-corrected imipramine plasma concentration...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.